Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/9/2019
SIETES contiene 92806 citas

 
 
 1 a 20 de 78 siguiente >>
Presentar resultados
Seleccionar todas
2. Cita con resumen
Thielking M. FDA panel says overdose antidote should be prescribed with opioids. STAT Morning Rounds 2018:3. [Ref.ID 102906]
3. Cita con resumen
Darrow JJ, Avorn J, Kesselheim AS. The FDA breakthrough-drug designation - Four years of experience. N Engl J Med 2018;378:16 de abril. [Ref.ID 102515]
4.Enlace a cita original Cita con resumen
Chin PKL, Doogue MP. Long-term prescribing of new oral anticoagulants. Australian Prescriber 2016;39:200-4. [Ref.ID 101021]
5. Cita con resumen
Connolly SJ, Milling Jr TJ, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albadalejo P, López-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M, for the ANNEXA-4 Investigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibotors. N Engl J Med 2016;375:1131-41. [Ref.ID 100767]
6. Cita con resumen
Anónimo. Idarucizumab. Prescrire 2016;36:494-9. [Ref.ID 100551]
7. Cita con resumen
Gómez-Outes A, Lecumberri R. Antídotos de los nuevos anticoagulantes orales: realidad y expectativas. Med Clin (Barc) 2016;146:488-90. [Ref.ID 100372]
8. Cita con resumen
Buckley NA, Dawson AH, Isbister GK. Treatments for paracetamol poisoning. BMJ 2016;353:i2579. [Ref.ID 100311]
9. Cita con resumen
Husted S, Verheugt FWA, Comuth WJ. Reversal strategies for NOACs: state of development, possible clinical applications and future perspectives. Drug Saf 2016;39:5-13. [Ref.ID 100083]
10. Cita con resumen
Anónimo. Idarucizumab (Praxbind) - An antidote for dabigatran. The Medical Letter on Drug and Therapeutics Bulletin 2015;57:157-8. [Ref.ID 99816]
11.Tiene citas relacionadas
Connors JM. Antidote for factor Xa anticoagulants. N Engl J Med 2015;373:2471-2. [Ref.ID 99801]
12.Tiene citas relacionadas Cita con resumen
Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015;373:2413-24. [Ref.ID 99658]
13. Cita con resumen
Anónimo. Drug problems: dangerous decision-making at the FDA. POGO. Project on Government Oversight 2015:15 de octubre. [Ref.ID 99569]
14. Cita con resumen
Anónimo. FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa. U.S. Food and Drug Administration 2015:16 de octubre. [Ref.ID 99566]
15. Cita con resumen
Glund S, Stangier J, Schmohl M, Gansser D, Norris S, Van Ryn J, Lang B, Ramael S, Moschetti V, Gruenenfelder F, Reilly P, Kreuzer J. Articles Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015;386:680-90. [Ref.ID 99494]
16.Tiene citas relacionadas
Bauer KA. Targeted anti-anticoagulants. N Engl J Med 2015;373:569-71. [Ref.ID 99488]
17.Tiene citas relacionadas Cita con resumen
Pollack Jr CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FV, Stangier J, Steiner T, Wang B, Kam CW, Weitz JL. Idarucizumab for dabigatral reversal. N Engl J Med 2015;373:511-20. [Ref.ID 99487]
18.Tiene citas relacionadas Cita con resumen
Dear JW, Antoine DJ, Park BK. Where are we now with paracetamol?. BMJ 2015;351:h3705. [Ref.ID 99251]
19. Cita con resumen
Anónimo. Intranasal naloxone for treatment of opioid overdose. Med Lett Drugs Ther 2014;56:21-2. [Ref.ID 97422]
20.Tiene citas relacionadas Cita con resumen
Bateman N, Dear JW, Thanacoody HKR, Thomas SHL, Eddleston M, Sandilands EA, Coyle J, Cooper JG, Rodríguez A, Butcher I, Lewis SC, Vliegenthart ADB, Veiraiah A, Webb DJ, Gray A. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet 2014;383:697-704. [Ref.ID 97150]
Seleccionar todas
 
 1 a 20 de 78 siguiente >>